Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.3.1.900
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 9 Months Ended 12 Months Ended
Feb. 02, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2005
USD ($)
Aug. 31, 2015
Nov. 30, 2015
USD ($)
CompensationPlan
Segments
Deliverables
Agreement
shares
Nov. 30, 2014
USD ($)
shares
Aug. 25, 2011
USD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Number of reportable segment | Segments         2    
Concentration risk related to supplier         Company depends on one supplier for the source of its collection kits    
Number of deliverables for revenue recognized | Deliverables         2    
Period of doubtful for accounts receivable due from client         30 days 21 years  
Contracted storage periods option two         21 years    
Contracted storage periods option one         1 year    
Contracted storage periods option three         Lifetime    
Deferred revenue recognition period         12 months    
Number of licensing agreement made by entity | Agreement         12    
Number of license agreement | Agreement         2    
Cash required to be deposited in bank for issuance of letter of credit         $ 200,000    
Certificate of deposit with a principal balance         200,000    
Cash transferred to trust             $ 2,500,000
Impairment on long lived assets         0 $ 0  
Equity method investment, impairment loss         684,000    
Minimum percentage probability of realized tax benefit on settlement       50.00%      
Provisions for interest or penalties related to uncertain tax positions         0 0  
Uncertain tax provisions         0 0  
Advertising cost included in selling, general and administrative expenses         756,000 621,000  
Unrealized gain(loss) on marketable securities         169,932 0  
Payment warranty     $ 50,000        
Increased payment warranty $ 75,000            
Additional payment warranty $ 10,000            
Reserves recorded under programs         $ 17,000 17,000  
Number of employee stock based compensation plan | CompensationPlan         3    
Stock option compensation expense         $ 603,000 $ 404,000  
Saneron [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Ownership interest         33.00% 33.00%  
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Non-Controlling interest after merger   43.42%          
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   260,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 1,924,000          
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   195,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 3,900          
Employee Stock Incentive Plan [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Number of outstanding options excluded from computation of diluted earnings per share | shares         225,000 271,000  
Other Income and Expense [Member]              
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]              
Unrealized holding gain (loss), trading securities         $ (1,600) $ (32,000)  
Realized gains on disposition of available for sale securities         $ 24,000